NCT05890131 (EMAIL-HF) is a NA clinical trial of Digital letter in Heart Failure, sponsored by Morten Schou.

Who is sponsoring NCT05890131?

NCT05890131 is sponsored by Morten Schou.

What drugs are being tested in NCT05890131?

Interventions in NCT05890131: Digital letter.

What condition does NCT05890131 study?

NCT05890131 studies Heart Failure.

Is NCT05890131 still recruiting?

NCT05890131 is currently completed. Last updated 13 April 2026.

Last reviewed 2026-04-13 · How we verify

NCT05890131: EMAIL-HF

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Implementation of SGLT-2 Inhibitors in Patients With Heart Failure Through a New Digital Strategy

Completed NA Last updated 13 April 2026

What this trial tests

NA trial testing Digital letter in Heart Failure in 5,996 participants. Completed in 7 April 2026.

Timeline

3 May 2023

Primary endpoint
7 April 2026

7 April 2026

Quick facts

Lead sponsor	Morten Schou
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	other
Enrollment	5,996
Start date	3 May 2023
Primary completion	7 April 2026
Estimated completion	7 April 2026
Sites	5 locations across Denmark

Drugs / interventions tested

Digital letter

Conditions studied

Heart Failure — all drugs for Heart Failure →

Sponsor

Morten Schou

Who can join

20 and older, any sex, with Heart Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The implementation of new medical therapies and guidelines, is a long and complex process that takes up to 10 years on average. This prolonged process is a global challenge and is mainly due to the complexity of cross-institutional patient care, involving primary care, out-patient clinics, nursing homes and patient associations. The main objective of this clinical trial is to determine whether a new digital strategy that employs official digital letters to inform and invite patients to evaluate their eligibility for new therapies, specifically the sodium-glucose co-transporter-2 (SGLT-2) inhibitor for heart failure patients, can facilitate and optimise the implementation. The aim is to increase the number of eligible patients with heart failure who start taking SGLT-2 inhibitors and reduce the time it takes to initiate treatment compared to the current process. Ultimately, this approach may improve patient outcomes.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Digital implementation strategy to increase SGLT2 inhibitor uptake in heart failure: Study design of EMAIL-HF.
Elmegaard M, Køber L, Ersbøll MK, Lange T, et al · · 2025 · cited 2× · PMID 40853763 · DOI 10.1002/ehf2.15398

Verify or expand the search:

Other recruiting trials for Heart Failure

Currently open trials in the same condition.

NCT06118983 — Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF) · NA · recruiting
NCT07496372 — Efficacy and Safety of Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Injection (HiCM-188) in Advanced Heart · Phase 3 · recruiting
NCT07527156 — Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure · Phase 4 · recruiting
NCT07263035 — Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure · Phase 4 · recruiting
NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting

Other Morten Schou trials

Trials by the same sponsor.

NCT03198585 — Empagliflozin in Heart Failure Patients With Reduced Ejection Fraction · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05890131 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Morten Schou
Last refreshed: 13 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05890131.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing